Document Type : Original Article


1 Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Neurology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Clinical Pharmacy, School of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran

4 Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran

5 Department of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran


Background: Fatigue is a common complication associated with multiple sclerosis (MS). The aim of this study was to evaluate the impact of dalfampridine and amantadine on fatigue in patients with MS.
Methods: This was a randomized, double-blind, clinical trial on patients with MS. The recruited patients were adults (≥ 18 years old) diagnosed with MS; their Expanded Disability Status Scale (EDSS) was between 0.0 and 5.5, and their fatigue was confirmed by the Modified Fatigue Impact Scale (MFIS). They were randomly assigned to the amantadine (100 mg twice daily) and dalfampridine (10 mg twice daily) for eight weeks. The primary outcome was the improvement of fatigue score, and the secondary outcome was assessment of quality of life by the Short-Form Health Survey (SF-36) and any reported side effects.
Results: A total of 69 patients were recruited, and 54 of them were analyzed. The mean MFIS significantly improved in both groups after one and two months compared to baseline: amantadine: first month: 40.63 ± 14.35 (P = 0.040), second month: 36.56 ± 17.12 (P = 0.010); dalfampridine: first month: 38.29 ± 15.23 (P = 0.001), second month: 34.26 ± 18.30 (P = 0.001). However, the amount of changes from baseline was not significantly different (amantadine, P = 0.090; dalfampridine, P = 0.130). The amount of changes in quality of life showed no significant improvement (P = 0.210).
Conclusion: The results showed that dalfampridine was not different with amantadine in improving fatigue in patients with MS; besides, it showed an acceptable safety profile. Therefore, it can be considered as a possible beneficial therapeutic agent in MS fatigue.


  1. Wood B, van der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler 2013; 19(2): 217-24.
  2. Sandry J, Genova HM, Dobryakova E, DeLuca J, Wylie G. Subjective cognitive fatigue in multiple sclerosis depends on task length. Front Neurol 2014; 5: 214.
  3. Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM 2008; 101(1): 49-60.
  4. Shah A. Fatigue in multiple sclerosis. Phys Med Rehabil Clin N Am 2009; 20(2): 363-72.
  5. Lapierre Y, Hum S. Treating fatigue. Int MS J 2007; 14(2): 64-71.
  6. Zifko UA. Management of fatigue in patients with multiple sclerosis. Drugs 2004; 64(12): 1295-304.
  7. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996; 53(2): 185-8.
  8. Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. Clin Neurol Neurosurg 2013; 115(Suppl 1): S86-S89.
  9. Nourbakhsh B, Revirajan N, Waubant E. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemp Clin Trials 2018; 64: 67-76.
  10. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373(9665): 732-8.
  11. Broicher SD, Filli L, Geisseler O, Germann N, Zorner B, Brugger P, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol 2018; 265(5): 1016-25.
  12. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
  13. Khazaei M, Karevan A, Taheri M, Ghafouri-Fard S. Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis. Clin Transl Med 2019; 8(1): 20.
  14. Multiple Sclerosis Clinical Practice Guidelines. Fatigue and multiple sclerosis: Evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America; 1998.
  15. Ware JE. SF-36 health survey update. Spine (Phila Pa 1976) 2000; 25(24): 3130-9.
  16. Ghajarzadeh M, Jalilian R, Eskandari G, Ali SM, Reza AA. Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. Disabil Rehabil 2013; 35(18): 1509-12.
  17. Rafiei N, Sharifian S, Rafiey H, Behnampour N, Foroozesh K. Reliability and validity of Persian version of "Qualityof Life Index". J Mazandaran Univ Med Sci 2014; 24(116): 75-83. [In Persian].
  18. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 2010; 33(8): 1061-7.
  19. Kobelt G, Acosta C, Zhou J, Harrington A, Kinter E, Dong S, et al. PND139 - Impact of prolonged-release fampridine on fatigue among people with multiple sclerosis in a multi-country study. Value Health 2018; 21: S352.
  20. Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, et al. A Prospective, observational, cohort study to assess the efficacy and safety of prolonged-release fampridine in cognition, fatigue, depression, and quality of life in multiple sclerosis patients: The family study. Adv Ther 2021; 38(3): 1536-51.
  21. Morrow SA, Rosehart H, Johnson AM. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord 2017; 11: 4-9.
  22. Bakirtzis C, Konstantinopoulou E, Langdon DW, Grigoriadou E, Minti F, Nikolaidis I, et al. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. J Neurol Sci 2018; 395: 106-12.
  23. Rocca MA, Valsasina P, Colombo B, Preziosa P, Martinelli V, Falini A, et al. Modulation of cortico-subcortical functional connectivity occurs after symptomatic treatment of fatigue in patients with multiple sclerosis (P3.384). Neurology 2018; 90(15 Suppl): 3.
  24. Rocca MA, Valsasina P, Colombo B, Martinelli V, Filippi M. Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. Eur J Neurol 2021; 28(7): 2249-58.